$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Heidelberg, Germany, May 10, 2017 - Affimed N.V. (Nasdaq: AFMD) today announced that on May 17, 2017, the Company will release its financial results for the quarter ended March 31, 2017. The Company's management team will host a conference call to discuss the Company's financial results and recent corporate developments on Wednesday, May 17, 2017 at 8:30 a.m. ET. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 7342202.
| Local - Amsterdam, the Netherlands: | +31 (0) 20 716 8257 |
| Local - Copenhagen, Denmark: | +45 38 32 28 69 |
| Local - Frankfurt, Germany: | +49 (0) 69 2222 10620 |
| Local - Geneva, Switzerland: | +41 (0) 22 592 7953 |
| Local - London, U.K.: | +44 (0) 20 3427 1919 |
| Local - New York City, U.S.A.: | +1 646 254 3361 |
| Local - Paris, France: | +33 (0) 1 76 77 22 25 |
An audio webcast of the conference call can be accessed in the "Events" section on the "Investors & Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the webcast will be available on Affimed's website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected]
